
Your Feed
Linvoseltamab -Now Approved- Know Your Therapy Video is in production
Detecting Minimal Residual Disease | Dory Abelman, PhD(c) | IMS 2024
Talquetamab as a Bridging Therapy to CAR-T Treatment | Shebli Atrash, MD | IMS 2024
Talquetamab Use in Treating Relapsed Refractory Multiple Myeloma | Shebli Atrash, MD | IMS 2024
Results of a Phase 1 Clinical Trial of Belantamab Mafadotin in RRMM | Shebli Atrash, MD | IMS 2024
Future Directions & Challenges in MM Precursor Conditions | María-Victoria Mateos, MD, PhD| IMS 2024
Overall Survival with Cilta-cel vs Standard of Care in Lenalidomide Refractory MM | María-Victoria Mateos, MD, PhD | IMS 2024
Strategies used to Prevent T-cell Exhaustion in Myeloma | Hermann Einsele, MD, FRCP | IMS 2024
The Current Standard of Care in the Post-Transplant Setting | Fredrik Schjesvold, MD, PhD | IMS 2024
Risk Stratification for Smoldering Myeloma | Irene Ghobrial, MD | IMS 2024



